Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining more than 300…
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday’s session following third-quarter results. Jabil reported third-quarter fiscal 2024…
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday’s regular session. The market value of their…
Gold Rises 1%; Accenture Shares Surge After Q3 Results
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 50 points on Thursday.…
What’s Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients using TPST-1120 combined with atezolizumab and bevacizumab.
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today’s pre-market trading after the company disclosed a strategic partnership…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday’s pre-market session. The company’s market cap stands…
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday’s after-market session. The company’s market cap…
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
Tempest Announces Publication Of Data From Phase 1 Trial Of TPST-1120 In Patients With Advanced Solid Tumors In Journal Of Cancer Research Communications
TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data, Company preparing to